Quit Smoking Drugs Market Size, Latest Trends, Growth Rate, Key Drivers And Forecast To 2033

"The new report published by The Business Research Company, titled ""Quit Smoking Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the quit smoking drugs market size has grown rapidly in recent years. It will grow from $34.86 billion in 2023 to $39.69 billion in 2024 at a compound annual growth rate (CAGR) of 13.8%. The quit smoking drugs market size is expected to see rapid growth in the next few years. It will grow to $69.08 billion in 2028 at a compound annual growth rate (CAGR) of 14.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp

Rising Disease Prevalence Linked To Smoking Fuels Growth In Quit-Smoking Drug Market
The growing prevalence of numerous diseases due to smoking is expected to propel the growth of the quit-smoking drug market going forward. Smoking is the practice of inhaling and exhaling burning plant material vapors such as marijuana and hashish, tobacco, and others. Quit smoking drugs are used to reduce the urge to smoke by hampering the craving for tobacco in an individual, where it is used as a prescription medication to control nicotine withdrawal symptoms to aid in quitting smoking effectively. For instance, in May 2022, according to the World Health Organization (WHO), a Switzerland-based international public health organization, more than 8 million people will be killed each year by tobacco. Around 1.2 million of those fatalities are caused by non-smokers being exposed to secondhand smoke, while more than 7 million are caused by direct tobacco use. Furthermore, in 2021, according to the American Heart Association, a US-based Nonprofit organization, cardiovascular disease related to smoking claims the lives of over 480,000 adults annually in the United States. Therefore, the growing prevalence of numerous diseases due to smoking is driving the growth of the quit-smoking drug market.

Innovative Product Strategies Drive Growth In The Quit Smoking Drugs Market
Product innovations are a key trend in gaining popularity in the quit smoking drugs. Major companies operating in the quit-smoking drug market are focused on innovating products to strengthen their position in the market. For instance, in August 2022, Swedish Match AB, a Sweden-based tobacco company, launched ZYN Tobacco Gold, a tobacco flavored, nicotine pouch in travel retail. Tobacco Gold is available in medium (3 mg) and strong (6 mg) strengths. The pouches' sweet tobacco flavor, which is reminiscent of dried fruit, wood, and caramel, satisfies consumer desires since tobacco has emerged as the most popular flavor to help consumers opt for reduced-risk alternatives that are both tobacco-free and smoke-free. It provides a solution for cigarette smokers who not only want to prevent the consumption of tobacco but also enjoy a nicotine kick in smoke-free environments.

The quit smoking drugs market covered in this report is segmented -

1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets
2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs
3) By Distribution: Drug Store, Online Pharmacies,, Retail Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9247&type=discount

Major companies operating in the quit smoking drugs market report are 22nd Century Group, Alkalon A/S, Cipla Limited, Dr. Reddy's Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Novartis AG, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Laboratoires Pierre Fabre, Takeda Pharmaceutical Company, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, Rusan Pharma Ltd., Axsome Therapeutics, BioCorRx Inc., BGP Pharma UAB, Bionorica SE, Cambrex Corporation, Chrono Therapeutics Inc., Coeptis Pharmaceuticals Inc., CV Sciences Inc., D-Pharm Ltd., DURECT Corporation, Egalet Corporation, Ennaid Therapeutics LLC, Fertin Pharma A/S, Gilla Inc., H&T Presspart Manufacturing Ltd., Hikma Pharmaceuticals PLC, Innovus Pharmaceuticals Inc., IntelGenx Technologies Corp. .

Contents of the report:
1. Executive Summary
2. Quit Smoking Drugs Market Report Structure
3. Quit Smoking Drugs Market Trends And Strategies
4. Quit Smoking Drugs Market - Macro Economic Scenario
5. Quit Smoking Drugs Market Size And Growth
…..
27. Quit Smoking Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.